Many of the responses to the COVID pandemic fall out of the realm of “health economics,” but there remain human activities in our “domain” as health economists. What can we learn about these from COVID?
Other featured articles
Economic Incentives for Administrative Simplification
In the US health care system, payers, health systems, physicians, other clinicians, drug companies, pharmacies, and pharmacy benefit managers all earn more revenue because of administrative complexity.
Private Equity Investment as a Divining Rod for Market Failure: Policy Responses to Harmful Physician Practice Acquisitions
It is unclear whether private equity investment is itself a problem or whether, in the absence of private equity, other sources of capital—such as public equity, venture capital, health systems, and insurers—would similarly exploit existing market failures and legal loopholes in the healthcare system.
Medical Device Regulation and Reimbursement: What the Pandemic Revealed
Join Schaeffer Center for a discussion on the challenges and opportunities facing the FDA and CMS in an age of breakthrough medical devices.
Medicare Coverage of Innovative Technologies: The U.S. Should do More to Speed Entry of Breakthrough Devices to Market
Schaeffer Center Expert Joe Grogan provides background on the proposed rule – Medicare Coverage of Innovative Technologies (MCIT) – and argues eliminating MCIT would abandon attempts to jumpstart American medical device innovation while also denying patients quick access to technologies that can improve their lives and their health.
About this section
Healthcare reform should hinge on improving value, reducing waste, and bettering the health outcomes of patients. The Schaeffer Center is a pioneer in posing solutions to enhance the value of healthcare services and expand their reach.